Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1849 1
1855 1
1867 1
1871 1
1875 1
1878 1
1880 1
1884 1
1890 1
1892 3
1895 1
1901 1
1902 1
1903 3
1906 1
1908 2
1910 1
1911 1
1913 4
1914 5
1915 2
1916 1
1917 1
1920 3
1922 3
1923 3
1924 1
1925 1
1926 2
1927 1
1928 1
1929 3
1930 2
1933 2
1934 1
1935 2
1936 2
1937 2
1938 1
1939 4
1940 1
1941 2
1942 2
1943 1
1944 4
1945 55
1946 219
1947 255
1948 271
1949 167
1950 53
1951 67
1952 162
1953 1210
1954 1649
1955 1876
1956 1706
1957 1883
1958 1735
1959 847
1960 135
1961 124
1962 168
1963 395
1964 791
1965 3646
1966 6143
1967 7043
1968 7706
1969 8892
1970 10103
1971 10742
1972 11584
1973 12536
1974 12873
1975 12858
1976 13849
1977 13894
1978 14600
1979 15356
1980 15187
1981 16147
1982 17749
1983 18951
1984 19893
1985 20661
1986 21222
1987 22077
1988 23366
1989 26081
1990 28225
1991 28777
1992 29400
1993 31487
1994 32811
1995 33892
1996 35233
1997 36198
1998 37586
1999 39149
2000 41616
2001 45559
2002 49388
2003 51583
2004 52903
2005 56519
2006 62415
2007 66932
2008 71592
2009 76462
2010 83046
2011 90148
2012 94273
2013 99041
2014 102411
2015 104273
2016 105120
2017 109724
2018 114901
2019 117478
2020 129768
2021 135248
2022 137529
2023 125902
2024 51251
2025 4

Text availability

Article attribute

Article type

Publication date

Search Results

2,617,884 results

Results by year

Filters applied: . Clear all
Page 1
Ginkgo biloba.
Sierpina VS, Wollschlaeger B, Blumenthal M. Sierpina VS, et al. Am Fam Physician. 2003 Sep 1;68(5):923-6. Am Fam Physician. 2003. PMID: 13678141 Free article. Review.
Ginkgo biloba is commonly used in the treatment of early-stage Alzheimer's disease, vascular dementia, peripheral claudication, and tinnitus of vascular origin. Multiple trials investigating the efficacy of ginkgo for treating cerebrovascular disease a …
Ginkgo biloba is commonly used in the treatment of early-stage Alzheimer's disease, vascular dementia, periphera …
Overview of late-onset psychoses.
Devanand DP, Jeste DV, Stroup TS, Goldberg TE. Devanand DP, et al. Int Psychogeriatr. 2024 Jan;36(1):28-42. doi: 10.1017/S1041610223000157. Epub 2023 Mar 3. Int Psychogeriatr. 2024. PMID: 36866576 Review.
In delirium, psychosis is common but controlled evidence is lacking to support psychotropic medication use. Delusions and hallucinations are common in Alzheimer's disease, and hallucinations are common in Parkinson's disease and Lewy body dementia. ... …
In delirium, psychosis is common but controlled evidence is lacking to support psychotropic medication use. Delusions and hallucinations are …
Alzheimer's Disease and Exercise: A Literature Review.
Cass SP. Cass SP. Curr Sports Med Rep. 2017 Jan/Feb;16(1):19-22. doi: 10.1249/JSR.0000000000000332. Curr Sports Med Rep. 2017. PMID: 28067736 Review.
Alzheimer's disease (AD) is a progressive neurodegenerative disease that impairs memory and cognitive judgment. ...Exercise has been shown to have fewer side effects and better adherence compared to medications....
Alzheimer's disease (AD) is a progressive neurodegenerative disease that impairs memory and cognitive judgment. ...Exer …
Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.
Calsolaro V, Femminella GD, Rogani S, Esposito S, Franchi R, Okoye C, Rengo G, Monzani F. Calsolaro V, et al. Pharmaceuticals (Basel). 2021 Mar 9;14(3):246. doi: 10.3390/ph14030246. Pharmaceuticals (Basel). 2021. PMID: 33803277 Free PMC article. Review.
Dementia affects about 47 million people worldwide, number expected to exponentially increase within 30 years. Alzheimer's disease (AD) is the most common dementia type, accounting on its own for almost 70% of all dementia cases. ...
Dementia affects about 47 million people worldwide, number expected to exponentially increase within 30 years. Alzheimer's …
Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel.
Kales HC, Gitlin LN, Lyketsos CG; Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Kales HC, et al. J Am Geriatr Soc. 2014 Apr;62(4):762-9. doi: 10.1111/jgs.12730. Epub 2014 Mar 17. J Am Geriatr Soc. 2014. PMID: 24635665 Free PMC article. Review.
Noncognitive neuropsychiatric symptoms (NPS) of dementia (aggression, agitation, depression, anxiety, delusions, hallucinations, apathy, disinhibition) affect individuals with dementia nearly universally across dementia stages and etiologies. ...Although the …
Noncognitive neuropsychiatric symptoms (NPS) of dementia (aggression, agitation, depression, anxiety, delusions, hallucinations, apat …
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Rogowska M, Thornton M, Creese B, Velayudhan L, Aarsland D, Ballard C, Tsamakis K, Stewart R, Mueller C. Rogowska M, et al. Drugs Aging. 2023 Jan;40(1):21-32. doi: 10.1007/s40266-022-00992-5. Epub 2022 Dec 14. Drugs Aging. 2023. PMID: 36513918 Free PMC article. Review.
The aim of this review is to provide an update on findings on adverse outcomes and clinical implications of antipsychotic use in dementia. These medications may increase mortality and can be associated with adverse events including pneumonia, cerebrovascular events, …
The aim of this review is to provide an update on findings on adverse outcomes and clinical implications of antipsychotic use in dementia …
Dementia.
Cunningham EL, McGuinness B, Herron B, Passmore AP. Cunningham EL, et al. Ulster Med J. 2015 May;84(2):79-87. Ulster Med J. 2015. PMID: 26170481 Free PMC article. Review.
The most common of these is Alzheimer's disease (50-75%) followed by vascular dementia (20%), dementia with Lewy bodies (5%) and frontotemporal lobar dementia (5%). ...Acetylcholinesterase inhibitors and memantine are the only medicati …
The most common of these is Alzheimer's disease (50-75%) followed by vascular dementia (20%), dementia wi …
Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.
Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, Kumar S, Colman S, Pollock BG, Mulsant BH, Rajji TK. Davies SJ, et al. J Psychopharmacol. 2018 May;32(5):509-523. doi: 10.1177/0269881117744996. Epub 2018 Jan 17. J Psychopharmacol. 2018. PMID: 29338602 Free PMC article.
INTRODUCTION: Behavioural and psychological symptoms of dementia (BPSD) include agitation and aggression in people with dementia. ...Additional guidance is given on use of electroconvulsive therapy, optimization of existing cholinesterase inhibitors/memantine, and u …
INTRODUCTION: Behavioural and psychological symptoms of dementia (BPSD) include agitation and aggression in people with dementia …
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].
Lin JS, O'Connor E, Rossom RC, Perdue LA, Burda BU, Thompson M, Eckstrom E. Lin JS, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Nov. Report No.: 14-05198-EF-1. PMID: 24354019 Free Books & Documents. Review.
Treatment (Key Questions 4-5): We identified one systematic review and 131 additional studies that addressed the treatment or management of mild to moderate dementia and/or MCI. Pharmacologic Interventions: Overall, based on one systematic review (50 trials) and 14 subsequ …
Treatment (Key Questions 4-5): We identified one systematic review and 131 additional studies that addressed the treatment or management of …
Diabetes Therapies for Dementia.
Moran C, Callisaya ML, Srikanth V, Arvanitakis Z. Moran C, et al. Curr Neurol Neurosci Rep. 2019 Jul 12;19(8):58. doi: 10.1007/s11910-019-0973-4. Curr Neurol Neurosci Rep. 2019. PMID: 31300920 Review.
This review describes the scientific data available on the use of T2D medications for the risk reduction or management of dementia, in people with and without T2D. ...Current evidence does not support the repurposing of T2D medications for dementia ris …
This review describes the scientific data available on the use of T2D medications for the risk reduction or management of dementia …
2,617,884 results
You have reached the last available page of results. Please see the User Guide for more information.